Kimberly-Clark's Risky Bet on Tylenol Amid Political Heat

Kimberly-Clark, a big name in consumer goods, just made a bold move. They bought Kenvue, the company behind Tylenol. But this deal didn't go over well with Wall Street. Their stock took a huge hit, the worst since the big crash in 1987. Shares dropped by 15%, which is a lot. Why did they do it? They're betting Tylenol can handle some serious heat. President Trump and Health Secretary Kennedy have been targeting Tylenol. They've made some big claims about Tylenol and autism, but these claims aren't proven. It's a risky bet for Kimberly-Clark. Meanwhile, Novo Nordisk has been spending big bucks on ads. They've spent about $7. 5 million on weight loss searches. Even though their drug, Ozempic, isn't approved for weight loss, they've been getting lots of visits to their website. It's a clever way to get around advertising rules. Pfizer isn't happy about this. They've sued Novo Nordisk and Metsera, a startup. Pfizer thinks Novo is trying to block competition in the weight-loss market. They've filed lawsuits to stop Novo from buying Metsera. Novo and Metsera say Pfizer's claims are nonsense. Telehealth companies are also jumping on the GLP-1 bandwagon. They're offering microdosed versions of these drugs. Celebrities like Rebel Wilson and Andy Cohen are promoting these programs. It's a trend that's gaining traction, but is it really helpful for patients?